Foghorn Therapeutics (FHTX) Enterprise Value (2020 - 2026)

Foghorn Therapeutics' Enterprise Value history runs 8 years deep, the most recent figure standing at -$88.9 million for Q1 2026.

• In Q1 2026, Enterprise Value fell 45.7% year-over-year to -$88.9 million; the TTM figure through Mar 2026 stood at -$88.9 million (down 45.7% YoY), while the FY2025 annual figure was -$82.1 million, down 48.1% from the prior year.
• Enterprise Value for Q1 2026 stood at -$88.9 million, down from -$82.1 million in the prior quarter.
• The five-year high for Enterprise Value was -$50.6 million in Q1 2023, with the low at -$213.6 million in Q1 2022.
• The 5-year median for Enterprise Value is -$73.8 million (2025), against an average of -$82.4 million.
• The sharpest annual moves came in 2022 and 2023: Enterprise Value tumbled 221.52% in 2022, then soared 76.3% in 2023.
• Foghorn Therapeutics' Enterprise Value stood at -$52.2 million in 2022, then slumped by 53.86% to -$80.3 million in 2023, then jumped by 30.97% to -$55.5 million in 2024, then tumbled by 48.1% to -$82.1 million in 2025, then slipped by 8.26% to -$88.9 million in 2026.
• Business Quant data shows FHTX's Enterprise Value at -$88.9 million in Q1 2026, -$82.1 million in Q4 2025, and -$90.6 million in Q3 2025.